Abstracts tagged "inflammation and psoriasis"

Abstract Number: 15L • 2016 ACR/ARHP Annual Meeting
Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis vulgaris and Normalizes Skin Pathology Via Concurrent Regulation of IL-17 and IL-10 Levels
Alexandra Zanin-Zhorov¹, Jonathan Weiss¹, Alissa Trzeciak¹, Carmen Arencibia¹, Seetharam Polimera¹, Wei Chen¹, Jingya Zhang¹, Melanie Nyuydzefe¹, Judilyn Fuentes-Duculan², Kathleen Bonifacio², Norma Kunjravia², Inna Cueto², Mark Berger¹, James Krueger², Samuel Waksal¹ and John Ryan¹, ¹Kadmon, New York, NY, ²Rockefeller University, New York, NY

Background/Purpose: Rho-associated kinase 2 (ROCK2) was shown to be implicated in regulation of autoimmunity in mice and humans1. Previous findings demonstrated that oral administration of…
Abstract Number: 2704 • 2016 ACR/ARHP Annual Meeting
Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Psoriasis
Vishal Deshmukh¹, Melinda Pedraza¹, Maureen Ibanez¹, Luis Dellamary¹, Josh Stewart¹, Timothy Seo¹, Benoit Melchior¹, John Hood² and Yusuf Yazici¹, ¹Samumed, LLC, San Diego, CA, ²Samumed, LLC (formerly), San Diego, CA
Background/Purpose: Psoriasis is an auto-immune disease of the skin, characterized by inflammation and fibrosis producing patches of red, itchy and scaly skin. Wnt signaling plays…
Abstract Number: 2934 • 2016 ACR/ARHP Annual Meeting
Clinical Assessment of the Monoclonal Anitbody, PRX003, a Potential Novel Treatment for Th17-Mediated Inflammatory Disease
Gene G. Kinney¹, Kenneth Flanagan¹, Michael Skov¹, Ronald Goldblum², Sue Griffith³, Robin M. Barbour¹, Wagner Zago¹, Ted Yednock¹, Martin Koller¹ and Dan Ness¹, ¹Prothena Biosciences Inc, South San Francisco, CA, ²Carlsbad Pharmaceutical Consulting, Inc., Carlsbad, CA, ³ClinPharma Services, Inc, San Diego, CA
Background/Purpose: Melanoma cell adhesion molecule (MCAM; CD146) is expressed on the surface of Th17 cells, which have the capacity to produce IL-17 and a multitude…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].